Meritz Securities: “A long-term approach is necessary, considering the grace period until 2032.”
"Samsung Biologics Poised for Growth with Plant 5 and Biosecurity Law"
There is an evaluation that Samsung Biologics' stock could rise in the short term if the U.S. Biosecurity Law is passed. On the 7th, Kim Jun-young of Meritz Securities stated, “Samsung Biologics is a…